Evaluation of a New Score Associated with Acute Kidney Injury in Patients Treated with Cisplatin Based EXTREME Regimen

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Apr 2

PMID 38566065

Authors

Francois Avry

Charles Roseau

Zoe Leguay

Sixtine Brabant

Alexandre Ganea

Elise Champeaux-Orange

Veronique Priou

Affiliations

Soon will be listed here.

Abstract

Background: This study evaluates the association of diuresis and hydration through a new monitoring indicator called and the risk of acute kidney injury in patients treated with cisplatin based-EXTREME regimen.

Methods: We retrospectively reviewed all the cycles of patients with recurrent and/or metastatic head and neck cancer who received cisplatin based-EXTREME regimen from June 2008 to July 2022. Hydration regimen, urine output and concomitant treatments data were collected on the day of cisplatin infusion and the following day of each course received.

Results: Of the 110 courses received by 46 patients, 38 (34.5%) results in AKI. No patient characteristics showed a significant difference between AKI (70%) and non-AKI (30%) group. In univariate analysis, dose reduction of cisplatin (odds ratio = 0.166 [0.04; 0.75], p = 0.01)) and >8 (odds ratio = 0.316 [0.133; 0.755], p = 0.015) and cardiac treatments (odds ratio = 3.24 [1.26; 8.52], p = 0.02) were significantly associated with AKI risk. In multivariate analysis, cisplatin dose reduction (odds ratio = 0.129 [0.0241; 0.687], p = 0.016) and >8 (odds ratio = 0.184 [0.0648; 0.523], p = 0.0015) were associated with a risk reduction of cisplatin-related AKI. Concomitant administration of cardiac treatments (odds ratio = 3.18 [1.1; 9.22], p = 0.033) showed an increased risk of cisplatin-related AKI.

Conclusion: The combination of diuresis and i.v. hydration through the composite score was shown to be associated with cisplatin-induced AKI risk in patients treated with cisplatin based EXTREME regimen. It could be used as a practical indicator to trigger specific clinical management to limit the risk of cisplatin induced AKI.

References

Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L . Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol. 2020; 21(1):19. PMC: 7052961. DOI: 10.1186/s40360-020-0398-3. View

Duan Z, Cai G, Li J, Chen X . Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol. 2020; 12:1758835920923430. PMC: 7238313. DOI: 10.1177/1758835920923430. View

Motwani S, McMahon G, Humphreys B, Partridge A, Waikar S, Curhan G . Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol. 2018; 36(7):682-688. PMC: 5946720. DOI: 10.1200/JCO.2017.75.7161. View

Koide H, Noda S, Okunuki Y, Owaki S, Shimizu T, Terada T . Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients. In Vivo. 2022; 36(5):2465-2472. PMC: 9463891. DOI: 10.21873/invivo.12982. View

Fukushima K, Okada A, Oe H, Hirasaki M, Hamori M, Nishimura A . Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity. Eur J Drug Metab Pharmacokinet. 2017; 43(2):193-203. DOI: 10.1007/s13318-017-0436-8. View

Samra B, Tam E, Baseri B, Shapira I . Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. J Investig Med. 2018; 66(7):1023-1030. DOI: 10.1136/jim-2018-000743. View

Pulte D, Brenner H . Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15(9):994-1001. PMC: 3228039. DOI: 10.1634/theoncologist.2009-0289. View

McDermott J, Bowles D . Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. Curr Treat Options Oncol. 2019; 20(5):43. DOI: 10.1007/s11864-019-0650-5. View

Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M . Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010; 102(6):966-71. PMC: 2844030. DOI: 10.1038/sj.bjc.6605578. View

10.

Auperin A . Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020; 32(3):178-186. DOI: 10.1097/CCO.0000000000000629. View

11.

Stewart D, Dulberg C, Mikhael N, Redmond M, Montpetit V, Goel R . Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997; 40(4):293-308. DOI: 10.1007/s002800050661. View

12.

Faig J, Haughton M, Taylor R, DAgostino Jr R, Whelen M, Porosnicu Rodriguez K . Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol. 2016; 41(5):432-440. PMC: 5145782. DOI: 10.1097/COC.0000000000000301. View

13.

Temam S, Pape E, Janot F, Wibault P, Julieron M, Lusinchi A . Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005; 62(4):1078-83. DOI: 10.1016/j.ijrobp.2004.12.062. View

14.

Lajer H, Kristensen M, Hansen H, Nielsen S, Frokiaer J, Ostergaard L . Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 2005; 56(5):535-42. DOI: 10.1007/s00280-005-1010-7. View

15.

Nagai N, Ogata H . The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats. J Pharm Sci. 1996; 85(7):720-4. DOI: 10.1021/js9505152. View

16.

Takeuchi K, Sogawa R, Tsuruhashi S, Motooka C, Kimura S, Shimanoe C . Antihypertensive Drug Combinations Modify Cisplatin-induced Acute Kidney Injury. In Vivo. 2022; 36(3):1391-1396. PMC: 9087053. DOI: 10.21873/invivo.12843. View

17.

Duffy E, Fitzgerald W, Boyle K, Rohatgi R . Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy. Clin J Oncol Nurs. 2018; 22(2):175-183. DOI: 10.1188/18.CJON.175-183. View

18.

Perazella M, Rosner M . Drug-Induced Acute Kidney Injury. Clin J Am Soc Nephrol. 2022; 17(8):1220-1233. PMC: 9435983. DOI: 10.2215/CJN.11290821. View

19.

Arany I, Safirstein R . Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23(5):460-4. DOI: 10.1016/s0270-9295(03)00089-5. View

20.

Kimura T, Ozawa T, Hanai N, Hirakawa H, Suzuki H, Hosoi H . Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg. 2018; 47(1):10. PMC: 5797413. DOI: 10.1186/s40463-018-0261-3. View